VEGFA and pachyonychia congenita: However, current therapies targeting the VEGF/VEGFR-2 pathway, such as TKIs and monoclonal antibodies, have shown limited clinical efficacy in PC, primarily because of the emergence of resistance and the activation of compensatory pathways.